AGENUS INC Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
AGENUS INC (AGEN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-07
- AGENUS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-06-30 was 0.00 shares.
- AGENUS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-03-31 was 3.00K shares.
- AGENUS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-09-30 was 58.00K shares.
- AGENUS INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-07 | 21.00K shares 10-Q · filed 2026-08-07 | |
| 2026-03-31 | 3.00K shares 10-Q · filed 2026-05-11 | ||
| 2025-09-30 | 58.00K shares 10-Q · filed 2025-11-10 | 58.00K shares 10-Q · filed 2025-11-10 | |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-07 | 0.00 shares 10-Q · filed 2026-08-07 | |
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-11 | ||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-10 | 0.00 shares 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |